Randomised phase II study of hepatic arterial infusion with floxuridine and dexamethasone with IV [intravenous] systemic chemotherapy with and without bevacisumab (mab to vascular endothelial growth factor-A) in patients with resected hepatic metastases from colorectal cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Dexamethasone; Floxuridine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Colorectal cancer; Liver metastases
Focus Therapeutic Use

Most Recent Events

19 Mar 2025 Status changed from active, no longer recruiting to completed.
19 Mar 2025 Status changed from active, no longer recruiting to completed.
04 Dec 2024 Planned End Date changed from 1 Nov 2024 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight